Results 211 to 220 of about 178,774 (332)

Ten‐Year Incidence, Risk Factors and Progression Rate of Macular Atrophy in Neovascular Age‐Related Macular Degeneration

Clinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background To evaluate the 10‐year cumulative incidence, progression rates, and risk factors for macular atrophy (MA) in neovascular age‐related macular degeneration (nAMD) patients receiving long‐term anti‐vascular endothelial growth factor (VEGF) therapy.
Francesco Romano, Marco Casaluci, Antonio Valastro, Matteo Airaldi, Paolo Milella, Francesco Pozzo Giuffrida, Elisa Cozzi, Andrea Aretti, Kelvin YC Teo, Chui Ming Gemmy Cheung, Marco Nassisi, Francesco Viola, Giovanni Staurenghi, Alessandro Invernizzi   +13 more
wiley   +1 more source

Warfarin and bevacizumab suppress tumor progression in pancreatic ductal adenocarcinoma by targeting EGFR-PI3K-Akt signaling: inhibition of proliferation/migration and apoptosis induction. [PDF]

Transl Cancer Res
Chen J, Ju J, Wang J, Yang L.
europepmc   +1 more source

Combination of monoclonal antibody (Bevacizumab) and chemotherapy (FOLFIRI) in palliative treatment of metastatic adenocarcinoma of the small bowel (SBC): case report and review of the literature. [PDF]

, 2009
Rafał Stec, Bartłomiej Grala, Michał Mączewski, Lubomir Bodnar, Arkadiusz Żegadło, Cezary Szczylik   +5 more
openalex  

Industry‐Reported Financial Relationships Among American Ophthalmology Society Board Members

Clinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background To assess financial disclosures of American ophthalmology society board members by comparing self‐reported disclosures with industry‐reported payments and examining characteristics linked to larger financial relationships. Methods In this retrospective, cross‐sectional study, we assessed all governance board members from American ...
Mostafa Bondok, Leonardo Lando, Anne Xuan‐Lan Nguyen, Michael Knafo, Albert Y. Wu   +4 more
wiley   +1 more source

Clinical study on Bevacizumab for macular edema induced by retinal vein occlusion

, 2014
Zhiguang Duan, Yun-Qin Jia, Ni Mo, Yin-Chao Chen, Liyun Yu, Tao Tao, Min Liu, Shi-Xue Pu   +7 more
openalex   +2 more sources

Overcoming Resistance Against HER2-Targeting Agents in Fifth-Line Therapy: Is There Still a Place for Bevacizumab in HER2+ Breast Cancer? [PDF]

, 2013
Florian Huemer, Simon Peter Gampenrieder, Alexander Schlattau, Richard Greil   +3 more
openalex   +1 more source

Newly identified properties of known pharmaceuticals and myxobacterial small molecules revealed by screening for autophagy modulators

The FEBS Journal, EarlyView.
Autophagy is a cellular degradation process involved in, for example, immune responses to pathogens and neurodegeneration. To identify modulators of autophagy, we developed a microscopy‐based screening assay and identified previously unknown autophagy‐modulating activities in known drugs and natural products from myxobacteria and fungi.
Janine Fichtner, Yan Yan Beer, H. G. Mauricio Ramm, Sabrina Mühlen, Frank Surup, Jennifer Herrmann, Toni Luise Meister, Stephanie Pfaender, Ursula Bilitewski, Mark Brönstrup, Rolf Müller, Manfred Wirth, Eeva‐Liisa Eskelinen, Ingo Schmitz   +13 more
wiley   +1 more source

Anlotinib or Bevacizumab Combined with Taxane/Capecitabine for the Second-Line or Subsequent Treatment of HER-2 Negative Metastatic Breast Cancer: A Retrospective Cohort Study. [PDF]

Drug Des Devel Ther
Xiang J, Sun P, Liu Z, Zhang Q, Song L, Liu J.   +5 more
europepmc   +1 more source

Efficacy of chemotherapy plus bevacizumab as first-line therapy in patients with metastatic colorectal cancer: a meta-analysis and up-date.

, 2015
Guoliang Zhang, Xile Zhou, Caizhao Lin
openalex   +1 more source

Use of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Patients with Metastatic Colorectal Cancer: A Single Center Experience

, 2022
Gülçin Şahingöz Erdal, İlkay Gültürk, Aykut Özmen, Seher Yıldız Tacar, Mesut Yılmaz, Deniz Tural   +5 more
openalex   +1 more source